Loading…
Silexion Therapeutics Corp is projected to rise to $2.64 by 2027, a +2% move from its current price of $2.59. SLXN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $2.41 | $2.59 | $2.78 | -0.11% |
| Jul 15 | $2.33 | $2.58 | $2.86 | -0.22% |
| Jul 16 | $2.28 | $2.58 | $2.93 | -0.33% |
| Jul 17 | $2.23 | $2.58 | $2.98 | -0.43% |
| Jul 18 | $2.19 | $2.58 | $3.03 | -0.54% |
| Jul 19 | $2.15 | $2.57 | $3.08 | -0.65% |
| Jul 20 | $2.12 | $2.57 | $3.12 | -0.76% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.12 | $2.57 | $3.12 | -0.76% |
| Week 2 | $1.94 | $2.55 | $3.35 | -1.51% |
| Week 3 | $1.81 | $2.53 | $3.53 | -2.26% |
| Week 4 | $1.71 | $2.51 | $3.69 | -3.00% |
| Week 5 | $1.62 | $2.49 | $3.84 | -3.74% |
| Week 6 | $1.54 | $2.47 | $3.97 | -4.47% |
| Week 7 | $1.47 | $2.46 | $4.09 | -5.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Silexion Therapeutics Corp is a biopharmaceutical company that discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.
It treats solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment.
The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Silexion Therapeutics Corp (SLXN) is a healthcare asset trading around $2.75 per share with a market cap of $2.92M and a current rank of 5420. The stock trades within a 30-day range of $1.28 to $5.89, reflecting notable volatility.
The near-term technical picture is bearish, with RSI14 at 30 and price below key moving averages. The SMA50 sits at $6.46 and the SMA200 at $22.32, providing overhead resistance. Support is identified at $2.69 and resistance at $6.33.
Longer-term forecasts show gradual upside, with the average price rising over time toward higher levels, and ROIs increasing in later years. The 2026 forecast shows an average of $2.75 with 0% ROI; the 2028-2050 windows show rising averages and double-digit ROIs, including 2028 avg $3.64 (32.3%), 2040 avg $5.74 (108.7%), and 2050 avg $8.10 (194.4%).
A major floor 89.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.5% away) — a key level to hold.
The nearest ceiling, 92.9% above — a clean break opens room to run.
A major ceiling 124.8% above — clearing it would confirm fresh momentum.
Key SLXN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SLXN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.69 | Sell | $2.64 | Sell |
| MA 10 | $2.65 | Sell | $2.68 | Sell |
| MA 20 | $2.73 | Sell | $2.73 | Sell |
| MA 50 | $2.21 | Buy | $2.43 | Buy |
| MA 100 | $1.78 | Buy | $2.31 | Buy |
| MA 200 | $2.25 | Buy | $4.87 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.45 | Neutral |
| Stoch RSI (14) | 8.14 | Buy |
| CCI (20) | -89.55 | Neutral |
| Williams %R (14) | -86.67 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -4.43 | Sell |
| Bollinger %B (20,2) | 0.26 | Neutral |
| Stochastic %K (14) | 13.33 | Buy |
| TRIX (15) | 0.45 | Buy |
| Awesome (5,34) | -0.32 | Sell |
| Ultimate (7,14,28) | 46.09 | Neutral |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 2.64 | Sell |
| ADX (14) | 14.22 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day range is $1.28 to $5.89, illustrating the recent trading band.
The sentiment is BEARISH with RSI14 at 30. The price remains below the SMA50 of $6.46 and the SMA200 of $22.32. Technicals point to a near-term foundation near support at $2.69 and resistance at $6.33.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.55 | $2.59 | $3.18 | 0% | Neutral | |
| $1.92 | $2.64 | $3.94 | +2% | Neutral | |
| $2.49 | $3.65 | $5.79 | +41% | Bullish | |
| $2.27 | $3.51 | $5.85 | +35% | Bullish | |
| $2.03 | $3.28 | $5.70 | +27% | Bullish | |
| $2.03 | $3.44 | $6.18 | +33% | Bullish | |
| $1.53 | $2.71 | $5.01 | +5% | Neutral | |
| $1.68 | $3.08 | $5.87 | +19% | Neutral | |
| $2.31 | $4.41 | $8.60 | +70% | Bullish | |
| $2.20 | $4.37 | $8.72 | +69% | Bullish | |
| $2.51 | $5.58 | $12.25 | +115% | Bullish | |
| $3.15 | $7.00 | $16.10 | +170% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.55 | $2.59 | $3.13 | +0.00% |
| August 2026 | $1.93 | $2.34 | $2.95 | -9.71% |
| September 2026 | $1.91 | $2.35 | $3.02 | +0.30% |
| October 2026 | $2.02 | $2.51 | $3.28 | +6.85% |
| November 2026 | $1.94 | $2.43 | $3.24 | -2.90% |
| December 2026 | $1.86 | $2.36 | $3.18 | -2.99% |
Click any year to see its month-by-month SLXN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SLXN is projected to trade between $2.55 and $3.18, averaging $2.59 — a potential gain of 0% from today's $2.59. Price action looks broadly range-bound.
Silexion Therapeutics Corp's 2027 outlook centres on $2.64, within a $1.92 to $3.94 range. That is up +2% on the projected 2026 average. That marks a +2% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, SLXN could reach as high as $5.79, with a base case around $3.65 and support toward $2.49 — roughly +41% from $2.59. Momentum favours further upside here.
Expect SLXN to range from $2.27 to $5.85 through 2029. The $3.51 average target implies a +35% move from current prices. That is -4% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
The SLXN price prediction for 2030 points to an average of $3.28 (low $2.03, high $5.70) — a potential gain of +27% on today's $2.59. Momentum favours further upside here.
In 2031, SLXN is projected to trade between $2.03 and $6.18, averaging $3.44 — a potential gain of +33% from today's $2.59. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Silexion Therapeutics Corp's 2032 outlook centres on $2.71, within a $1.53 to $5.01 range. That is -21% versus the projected 2031 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2033, SLXN could reach as high as $5.87, with a base case around $3.08 and support toward $1.68 — roughly +19% from $2.59. A consolidation phase looks the most probable path here.
Expect SLXN to range from $2.31 to $8.60 through 2034. The $4.41 average target implies a +70% move from current prices. That is up +43% on the projected 2033 average. Momentum favours further upside here.
The SLXN price prediction for 2035 points to an average of $4.37 (low $2.20, high $8.72) — a potential gain of +69% on today's $2.59. Buyers look set to stay in control over this stretch.
In 2040, SLXN is projected to trade between $2.51 and $12.25, averaging $5.58 — a potential gain of +115% from today's $2.59. That is up +28% on the projected 2035 average. Momentum favours further upside here.
Silexion Therapeutics Corp's 2050 outlook centres on $7.00, within a $3.15 to $16.10 range. That is up +25% on the projected 2040 average. That marks a +170% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in SLXN today (≈ 386.100386 SLXN) could be worth
$2,702.37
+$1,702.37 (+170%) by 2050 · US Dollar
Based on the average projected SLXN price of $7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SLXNwould be worth at today's price.
$1,000 invested in SLXN on Jul 10, 2025 (≈ 80.710248 SLXN) would be worth
$209.04
-$790.96 (-79.1%) today · 0.21× · US Dollar
Based on a SLXN entry price of $12.39 vs. today's $2.59.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.64 | $979.21 | -2.1% |
| 1 month ago | $3.06 | $846.41 | -15.4% |
| 3 months ago | $1.05 | $2,466.67 | +146.7% |
| 6 months ago | $2.12 | $1,221.7 | +22.2% |
| 1 year ago | $12.39 | $209.04 | -79.1% |
| All time (5.0y) ago | $144.9 | $17.87 | -98.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SLXN forecast.
Our base-case forecast reaches $5.20 around 2040.
Implied market cap at $5.20: $5.53M
The multi-year forecast projects a bullish tilt in the latter part of the horizon. In 2027 the average is $2.95 with ROI 7.1%; in 2028 the average is $3.64 with ROI 32.3%; in 2029 the average is $3.88 with ROI 41.2%; in 2030 the average is $3.55 with ROI 28.9%. The forecast continues with 2034 at $4.64 (68.5%), 2035 at $4.87 (77.2%), 2040 at $5.74 (108.7%), and 2050 at $8.10 (194.4%).
These figures reflect higher average prices and substantially higher ROIs later in the horizon, suggesting meaningful upside relative to today if conditions align. These are estimates, not guarantees. Risks include variability and volatility, with recent bearish sentiment in the near term and higher volatility (annualized volatility 200%).
Tap a question to reveal the answer.
The average forecast price for 2030 is $3.55 with an ROI of 28.9%.
Forecasts show a mix of neutral near term and bullish long term, with 2027 average $2.95 (ROI 7.1%), 2028 average $3.64 (ROI 32.3%), 2040 average $5.74 (ROI 108.7%), and 2050 average $8.10 (ROI 194.4%). These are estimates, not guarantees.
Yes. The forecast maximum for 2050 is $18.62, corresponding to an estimated ROI of 194.4%.
Current price is $2.75 and market cap is $2.92M.
The 30-day range is $1.28 to $5.89.
Silexion Therapeutics Corp Community Discussion
0Share your Silexion Therapeutics Corp price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.